The triptans: A summary

CNS Drugs

Volumn 12, Issue 5, 1999, Pages 403-417

  Tepper, Stewart J ^a,d   Rapoport, Alan M ^b,c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b NEW ENGLAND CENTER FOR HEADACHE   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Polyclinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALMOTRIPTAN; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIHISTAMINIC AGENT; ELETRIPTAN; FLUVOXAMINE; FROVATRIPTAN; NARATRIPTAN; ORAL CONTRACEPTIVE AGENT; RIZATRIPTAN; SEROTONIN 1 AGONIST; SUMATRIPTAN; TERFENADINE; ZOLMITRIPTAN;

DRUG EFFICACY; DRUG FORMULATION; DRUG INDUCED DISEASE; DRUG MECHANISM; HEADACHE; HUMAN; INTRANASAL DRUG ADMINISTRATION; MIGRAINE; NAUSEA; NEUROTRANSMISSION; ORAL DRUG ADMINISTRATION; PAIN; PARESTHESIA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RECTAL DRUG ADMINISTRATION; RECURRENT DISEASE; REVIEW; SEROTONINERGIC SYSTEM; SUBCUTANEOUS DRUG ADMINISTRATION; THORAX PAIN;

EID: 0032695536     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199912050-00007     Document Type: Review

References (96)

1. 1. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias, and facial pain. Cephalalgia 1988; 8 Suppl. 7: 1-96
2. 2. International Headache Society Committee on Clinical Trials in Migraine. Guidelines for controlled trials of drugs in migraine. 1st ed. Cephalalgia 1991; 11: 1-12
3. 3. Cox OR. Regression modes and life tables. JR Stat B 1972; 34: 187-202
4. 4. Rapoport AM, Visser WH, Cutler N, et al. Oral sumatriptan in preventing headache recurrence after treatment of migraine attacks with subcutaneous sumatriptan. Neurology 1995; 45: 1505-9
5. 5. Woods RP, Iacoboni M, Mazziotta JC. Brief report: bilateral spreading cerebral hypoperfusion during spontaneous migraine Headache. N Engl J Med 1994; 331: 1689-92
6. 6. Weiler C, May A, Limmroth V, et al. Brain stem activation in spontaneous human migraine attacks. Nat Med 1995; I: 658-60
7. 7. Goadsby PJ. Current concepts of the pathophysiology of migraine. In: Mathew NT, editor. Neurologic clinics of North America. Philadelphia (PA): WB Saunders, 1997; 15: 27-41
8. 8. Cutrer FM, Limmroth V. Waeber C, et al. New targets for anti-migraine drug development. In: Goadsby PJ, Silberstein SD, editors. Headache. Philadelphia (PA). Butterworth-Heinnemann, 1997: 59-72
9. 9. Edvinsson L, Goadshy PJ. Neuropeptides in headache. Eur J Neurol 1998; 5: 329-41
10. 10. Goadsby PJ. 5-HT 1B/1Dagonists in migraine: comparative pharmacology and its therapeutic implications. CNS Drugs 1998; 10: 271-86
11. 11. Fowler PA, Lacey LF, Thomas M, et al. The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan. Eur Neurol 1991; 31: 291-4
12. 12. Moore KHP, Hussey EK, Shaw S, et al. Safety, tolerability, and pharmacokinetics of sumatriptan in healthy subjects following ascending single intranasal doses and multiple intranasal doses. Cephalalgia 1997; 17: 541-50
13. 13. Pilgrim AJ. The clinical profile of sumatriptan: efficacy in migraine. Eur Neurol 1994; 34 Suppl. 2: 26-34
14. 14. Marlin G, Dixon R, Seaber E. Preclinical and clinical pharmacology of zolmitriptan (3IIC90): a novel antimigraine agent. In: Olesen J, Tfelt-Hansen P, editors. Headache treatment: trial methodology and new drugs. Philadelphia (PA): Lippincott-Raven, 1997: 257-62
15. 15. Seaber E, Dixon E, Veronese R, et al. The novel antimigraine drag 3IIC90 has no clinically significant interactions with likely concomitant medications [abstract]. Eur Neurol 1996; 3 Suppl. 5: 407
16. 16. Martin GR, Goadsby PJ. 3IIC90 (Zomig', zolmitriptan), a novel 5-HT1B/1D agonist for treatment of acute migraine: mechanism of action [abstract]. Neurology 1997; 48 (3): A67
17. 17. Package insert: rizatriptan (Maxalt™). West Point (PA): Merck, 1998
18. 18. Seiberras DG, Polvinao WJ, Gertz B-J, et al. Initial experience with MK-462 (rizatriptan): a novel 5-HT1D agonist. Br J Clin Pharmacol 1997; 43 (1): 49-54
19. 19. Goldberg MR, Lee Y, Ermlich S, et al. Single and multiple-dose pharmacokinetic and tolerability of rizatripan, a novel 5-HT 1D/1B agonist for migraine [abstract]. Headache 1997; 37: 310
20. 20. Cheng H, Polvino WJ, Sciberras D, et al. Pharmacokinetic and food interaction of MK-462 in healthy males. Biopharm Drug Dispos 1996; 17: 17-24
21. 21. Connor HE, Feriuk W, Beatte DT, el al. Naratriptan: biological profile in animal models relative to migraine. Cephalalgia 1997; 17: 145-52
22. 22. Kempsford RD, Baille P, Fuseau E. Oral naratriptan tablets (2.5-10mg) exhibit dose-proportional pharmacokinetics [abstract]. Cephalalgia 1997; 17: 408
23. 23. Fuseau E, Baille P, Kempsford RD. A study to determine the absolute oral bioavailability of naratriptan [abstract; also published in Headache 1997; 37: 309].Cephalalgia 1997; 17: 417
24. 24. Kempsford RD, Hoke JF, Huffman CS. The safety, tolerability and phamacokinetics of oral naratriptan in healthy subjects [abstract]. Headache 1997; 37: 316
25. 25. Sheftell F, Milton KA, James GC, et al. The pharmacokinetics and safety of eletriptan in volunteers and migraineurs [abstract]. Headache 1997; 37: 331
26. 26. Milton KA, Allen MJ, Abel S, et al. The safety, tolerability, pharmacokinetics and pharmacodynamics of oral and intravenous eletriptan, a potent and selective '5HT1p-like' receptor partial agonist [abstract; also published in Headache 1997; 37: 324]. Cephalalgia 1997; 17: 414
27. 27. Gupta P, Napler CM, Purdy J, et al. In Vitro profile of eletriptan, a new '5-HT ID-like' receptor partial agonist [abstract]. Headache 1997; 37: 311-2
28. 28. Milton KA, Allen MJ, Abel S, et al. The safety, tolerability and pharmacokinetics of oral eletriptan (UK-116,044), a potent and selective '5-HT 1D like' receptor agonist [abstract]. Cephalalgia 1996; 16: 368
29. 29. Buchan P. The pharmacokinetics of frovatriptan (VML 251/SB 209509, a potent selective S-HT 1B/1D agonist, following single dose administration by oral and intravenous routes to healthy male and female volunteers [abstract]. Headache 1998; 38: 376
30. 30. Ryan R, Key wood C, et al. A preliminary study of VML 251 (SB209509), a novel 5HT 1B/1D agonist for the treatment of acute migraine [abstract; also published in Headache 1997; 37: 329]. Cephalalgia 17: 418
31. 31. Cabarrocas X, Salva M. Pharmacokinetic and metabolic data on almotriptan, a new antimigraine drug [abstract]. Cephalalgia 1997; 17: 421
32. 32. Cabarrocas X, Fernandez FJ, Popescu G, et al. The pharmacokinetics and tolerability of almotriptan in renal impairment [abstract; poster no. 70]. Headache 1999; 39: 346
33. 33. Ferrari M. Migraine treatment: a review. Lancet 1998; 351: 1043-5
34. 34. Goadsby PJ. A triptan too far? J Neurol Neurosurg Psychiatry 1998; 64: 143-5
35. 35. Millson DS. Do we need another triptan for the acute treatment of headache? J Immunol Immunopharmacol 1998; 18: 99-104
36. 36. Physician's desk reference. 51st ed. Montvale (NJ): Medical Economics Company, 1997: 1099-102
37. 37. van Haarst AD, van Gerven JMA, Cohen AF, et al. The effects of moclobemide on the pharmacokinetics of the 5-HTI1B/1D agonist rizatriptan in healthy volunteers. Br J C lin Pharmacol 1999; 48: 190-6
38. 38. Cady RK, Dexter J, Sargent JD, et al. Efficacy of subcutaneous sumatriptan in repeated episodes of migraine. Neurology 1993; 43: 1363-8
39. 39. Cady RK, Wendt JK, Kirchner JR, et al. Treatment of acute migraine with subcutaneous sumatriptan. JAMA 1991; 265: 2831-5
40. 40. The Subcutaneous Sumatriptan International Study Group. Treatment of migraine attacks with sumatriptan. N Engl J Med 1991; 325: 316-21
41. 41. Gobel H, Baar H, Beikufner HD, et al. Practicability and acceptance of subcutaneous self-administration of the selective serotonin agonist sumatriptan. Headache 1998; 38: 267-9
42. 42. Pffaffenrath V, Cunin G, Sjonell G, et al. Efficacy and safety of sumatriptan tablets (25mg, 50mg, and 100mg) in the acute treatment of migraine: defining the optimum doses of oral sumatriptan. Headache 1998; 38: 184-90
43. 43. Salonen R, Ashford E, Dahlof C. Intranasal sumatriptan for the acute treatment of migraine. International Intranasal Sumatripan Study Group. J Neurol 1994; 241: 463-9
44. 44. The Finnish Sumatriptan Group. A placebo-controlled study of intranasal sumatriptan for the acute treatment of migraine. Eur Neurol 1991; 31: 332-8
45. 45. Peikert A, Becker WJ, Ashford HA, et al. Sumatriptan nasal spray - a dose-ranging study in the acute treatment of migraine. Eur J Neurol 1999; 6: 43-9
46. 46. Diamond S, Elkind A, Jackson T, et al. Multiple attack efficiency and tolerability of sumatriptan nasal spray in the treatment of migraine. Arch Fam Med 1998; 7: 234-40
47. 47. Ryan R, Elkind A, Baker CC, et al. Sumatriptan nasal spray for the acute treatment of migraine: results of two clinical studies. Neurology 1997; 49: 1225-30
48. 48. Tepper SJ, Cochran A, Hobbs S, et al. Sumatriptan suppositories for the acute treatment of migraine, InI J Clin Pract 1998; 1:31-5
49. 49. Tansey MJB, Pilgrim AJ, Martin PM. Long term experience with sumatriptan in the treatment of migraine. Eur Neurol 1993; 33: 310-5
50. 50. Reches A, Study Group et al. The long term tolerability, safety and efficacy of sumatriptan 20mg nasal spray in the acute treatment of migraine. Cephalalgia 1995; 15 Suppl. 14: 241
51. 51. Dahlof CGH, Boes-Hansen S, Cederberg C-G, et al. How does sumatriptan nasal spray perforn in clinical practice? Cephalalgia 1998; 18: 278-82
52. 52. Tepper SJ. Sumatriptan nasal spray [editorial]. Cephalalgia 1998; 18: 242
53. 53. MacIntyre PD, Bhargava B, Hogg KJ, et al. Effect of subcutaneous sumatriptan, a selective 5HTT agonist, on the systemic, pulmonary, and coronary circulation. Circulation 1993; 87: 401-5
54. 54. Maasen Van Den Brink AM, Reekers M, Bax WA, et al. Coronary side-effect potential of current and prospective antimigraine drugs. Circulation 1998; 98: 25-30
55. 55. O'Quinn S, Davis RL, Gutterman DL, et al. Prospective largescale study of the tolerability of subcutaneous sumatriptan for acute treatment of migraine. Cephalalgia 1999; 19: 223-31
56. 56. Rapoport AM, Ramadan NM, Adelman JU, et al. Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine: a multicenler, double-blind, placebo-controlled, dose range. Finding study. Neurology 1997; 49: 1210-8
57. 57. Solomon GD, Cady RK, Klapper JA, et al. Clinical efficacy and tolerability of 2,5mg zolmitriptan for the acute treatment of migraine. Neurology 1997; 49: 1219-25
58. 58. Gallagher RM. Comparison of zolmitriptan and sumatriptan for the acute treatment of migraine [poster II-G1-14]. Cephalalgia 1999; 19: 358
59. 59. International 3IIC90 Long-term Study Group. The long-term tolerability and efficacy of oral zolmitriptan (ZOMIG, 311C90) in the acute treatment of migraine. An international study. Headache 1998; 38: 399-400
60. 60. Zagami AS. 3IIC90: long-term efficacy and tolerability profile for the acute treatment of migraine. Neurology 1997; 48 Suppl. 3: S25-S28
61. 61. Ryan RE, Rapoport AM, Tolerability of Zomig for treating migraine in an open-label, continuation protocol. Headache 1998; 38: 173-83
62. 62. Klassen A, Elkind A, Asgharnejad M, et al. Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, parallel group study. Headache 1997; 37: 640-5
63. 63. Mathew NT, Mahnaz A, Peykamian M, et al. Naratriptan is effective and well tolerated in the acute treatment of migraine; results of a double-blind, placebo-controlled, crossover study. Neurology 1997; 49: 1485-90
64. 64. Naramig (naratriptan hydrochloride). Summary of product characteristics. Marketing authorisation RVG 21444, 1998
65. 65. Goadsby PJ, Asgharnejad M, Winter PD. Twenty-four hour maintenance of headache relief after treatment of migraine with naratriptan tablets: a review of data from controlled clinical trials [abstract]. Headache 1998; 38: 382
66. 66. Cioadsby PJ, Asghamejad M, Winter PD. Twenty-four hour maintenance of headache relief after treatment of migraine with naratriptan tablets: a review of data from controlled clinical trials [abstract; poster no. 16]. American Association for the Study of Headache Meeting: 1998 June 27; San Francisco, California
67. 67. Dahlof C, Hogenhuis L, Olesen J, et al. Early clinical experience with subcutaneous naratriptan in the acute treatment of migraine; a dose ranging study. Eur J Neurol 1998; 5: 469-77
68. 68. Millson D, Tepper S. Issues relating to the assessment of migraine recurrence following triptan therapy. Eur J Neurol 1999; 6: 1-2
69. 69. Sheftell F, Watson C, Pait DG, et al. Low headache recurrence with naratriptan: clinical parameters related to recurrence [abstract). Headache 1998; 38: 405
70. 70. Heywood J, Enahoro H, Winter P, et al. Tolerability and efficacy of oral naratriptan 2.5mg in the acute treatment of migraine over a 12 month period [abstract). J Neurol Sci 1997; 150: S34
71. 71. Teall J, Tuchman M, Cutler N, et al. Rizatriptan (Maxalt) for the acute treatment of migraine and migraine recurrence. A placebo-controlled, outpatient study. Headache 1998; 38: 281-7
72. 72. Kramer MS, Matzura-Wolfe D, Polis A, et al. A placebo-controlled crossover study of rizatriptan in the treatment of multiple migraine attacks. Neurology 1998; 51: 773-81
73. 73. Lines C, Visser WH, Vandormacl K, et al. Rizatriptan 5mg versus sumatriptan 50mg in the acute treatment of migraine. Headache 1997; 37: 319-20
74. 74. Ahrens SP, Farmer MV, Williams DL, the Rizatriptan Wafer Protocol 049 Study Group, et al. Efficacy and safety or rizatriptan wafer for the acute treatment of migraine. Cephalalgia 1994; 19: 525-30
75. 75. Block GA, Goldstein J, Polis A, et al., and the Rizatriptan Multicenter Study Groups. Efficacy and safety of rizatriptan versus standard care during long-term treatment for migraine. Head ache 1998; 38: 764-71
76. 76. Topper SJ Rizatriptan-a new agent for the treatment of migraine. Todays Ther Trends 1999; 17: 147-57
77. 77. Tfelt-Hansen P, Teall J, Rodriguez F, et al. Oral rizatriptan versus oral sumatriptan: a direct comparative study in the acute treatment of migraine. Headache 1998; 38: 748-55
78. 78. Goldstein J, Ryan R, Jiang K, et al. Crossover comparison of rizatriptan 10mg versus sumatriptan 25mg and 50mg in migraine. Headache 1998; 38: 737-47
79. 79. Visser WH, Jiang K. Effect of rizatriptan versus sumatriptan on migraine-associated symptoms [abstract). Neurology 1998: 50: A375
80. 80. Bornhof MK, Legg N, Paz J. Comparison of rizatriptan 10mg versus naratriptan 2.5mg in migraine [abstract; poster no. 65]. Headache 1999; 39: 344
81. 81. Dicner HC, Pascual J, Vega P. Comparison of rizatriptan 10mg versus zolmitriptan 2.5mg in migraine ;abstract: platform presentation]. Headache 1999; 39: 351
82. 82. Morgan P, Rance D, James G, et al. Comparative absorption and elimination of eletriptan in rat, dog, and human [abstract; poster no. 07-A-07). Cephalalgia 1997; 17: 414
83. 83. Jackson NC. A comparison of oral eletriptan (UK-116,044) (20-80 mg) and oral sumatriptan (100 mg) in the acute treatment of migraine. Cephalalgia 1996; 16: 368-9
84. 84. Gupta P, Napler CM, Purdy J, et al. In vitro profile of eletriptan, a new '5-HTID-like' receptor partial agonist [abstract]. Cephalagia 1996; 16: 368
85. 85. Poole PH, Eletriptan Steering Committee, Jackson NC. Measures of rapid resolution of migraine symptoms and patients acceptance to treatment following eletriptan, sumatriptan and placebo [abstract]. Neurology 1998; 50: A375
86. 86. Pryse-Phillips W, on behalf of the Eletriptan Steering Committee. Comparison of oral eletriptan (40-80 mg) and oral sumatriptan (50-100 mg) for the treatment of acute migraine: a randomised, placebo-controlled trial in sumatriptan-naive patients (abstract: posier no. II-GI-6]. Cephalalgia 1999; 19: 355-6
87. 87. Pitman V, Forster E, Jackson NJ. Comparison of oral eletriptan and oral sumatriptan for the acute treatment of migraine: combined analysis across three clinical trials [abstract; platform presentation]. Headache 1999; 39: 374
88. 88. Pitman V. Headache recurrence following single doses of oral eletriptan: review of clinical trial experience [abstract; poster II-GI-2]. Cephalalgia 1999; 19: 354
89. 89. Catteau A, Bechtel YC, Poisson N, et al. A population and family study of CYPIA2 using caffeine urinary metabolites. Eur J Clin Pharmacol 1995; 47: 423-340
90. 90. Zomig (zolmitriptan). Summary of product characteristes. Marketing authorisation PL12619/0116, 1997
91. 91. McDaris HL, Hutchison J, for the Frovatriptan Phase III Investigators. Frovatriptan - a review of overall clinical efficacy [abstract; poster II-GI-29]. Cephalalgia 1999; 19: 363-4
92. 92. Spierings ELH, Hutchison J, for the Frovatriptan Phase II and III Investigators. Frovatriptan a review of safety and tolerability [abstract; poster II-GI-42]. Cephalalgia 1999; 19: 367
93. 93. Goldstein J, Keywood C, Hutchison J. Low 24-hour recurrence during treatment with frovatriptan [abstract; poster II-GI-36]. Cephalalgia 1999; 19: 365-6
94. 94. Fleishaker JC, Ryan KK, Carel BJ, et al. Effect of MAO-A inhibition on the pharmacokinetic of the novel anti-migraine agent, almotriptan, in humans. 9th congress of the International Headache Society; 1999 Jun 22-26; Barcelona
95. 95. Cabarrocas X, Zayas JM. Efficacy data on oral almotriptan, a novel SHT-ID agonist [abstract; also published in Headache 1998; 38: 377]. Cephalalgia 1997; 17: 421
96. 96. Cabarrocas X, Zayas JM, Suris M. Equivalent efficacy of oral almotriptan, a new 5-HT agonist, compared with sumatriptan 100 mg [abstract]. Headache 1998; 38: 377